Pharmaceutical Collaboration Commits Up to $250 Million Over Eight Years; CRISPR Therapeutics Releases Data; Vivo Capital Closes Funding Round

A collaboration in the pharmaceutical industry will allocate up to $250 million over the next eight years. Separately, CRISPR Therapeutics released new data, and Vivo Capital secured additional funding. The eight-year collaboration involves a commitment of up to $250 million in investment. Simultaneously, CRISPR Therapeutics made public the details of its latest research findings. In other financial news, Vivo Capital successfully completed a fundraising round, adding to its investment capital.

Newsflash | Powered by GeneOnline AI
Date: May 9, 2025

Related posts:

Breakthrough Study Suggests Common Antibiotic Vancomycin Could Treat Specific Inflammatory Bowel Disease Alzheimer’s Research: 16 New Susceptibility Genes Identified Study Reveals Startling Impact of Abrupt PEPFAR Funding Cuts Study Maps Brain’s Real-Time Speech Processing Using AI and Electrocorticography

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後